Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Metabolic Health

A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation

A. M. Lynch; N. Pathak; V. Pathak; F. P. M. O’Harte; P. R. Flatt; N. Irwin; V. A. Gault A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation Diabetologia

Complications of obesity

D. Kinlen; D. Cody; D. O'Shea Complications of obesity Qjm

Obesity and carotid artery remodeling

M. Kozakova; C. Palombo; C. Morizzo; K. Højlund; M. Hatunic; B. Balkau; P. M. Nilsson; E. Ferrannini Obesity and carotid artery remodeling Nutr Diabetes

Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level

K. Kearns; A. Dee; A. P. Fitzgerald; E. Doherty; I. J. Perry Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level BMC Public Health

Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice

N. Irwin; I. A. Montgomery; R. C. Moffett; P. R. Flatt Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice Biochem Pharmacol
Insulin Resistance & Diabetes

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

N. Irwin; I. A. Montgomery; F. P. O'Harte; P. Frizelle; P. R. Flatt Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes Int J Obes (Lond)
Insulin Resistance & Diabetes

Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

N. Irwin; V. A. Gault; F. P. M. O'Harte; P. R. Flatt Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes Peptides
Insulin Resistance & Diabetes

Metabolomics in the developmental origins of obesity and its cardiometabolic consequences

M. F. Hivert; W. Perng; S. M. Watkins; C. S. Newgard; L. C. Kenny; B. S. Kristal; M. E. Patti; E. Isganaitis; D. L. DeMeo; E. Oken; M. W. Gillman Metabolomics in the developmental origins of obesity and its cardiometabolic consequences J Dev Orig Health Dis

New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders

N. Irwin; P. R. Flatt New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders World J Diabetes
Insulin Resistance & Diabetes

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

S. L. Craig; V. A. Gault; N. Irwin Emerging therapeutic potential for xenin and related peptides in obesity and diabetes Diabetes Metab Res Rev
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page8 Page9 Page10 … Page53 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI